var data={"title":"Asunaprevir (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Asunaprevir (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/795060?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=asunaprevir-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Asunaprevir (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537432\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sunvepra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537336\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihepaciviral, NS3/4A Protease Inhibitor (Anti-HCV);</li>\n      <li>\n        NS3/4A Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537360\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">\n      <b>Chronic hepatitis C (CHC):</b> Oral: <b>Note:</b> Treatment-naive patients include those with no prior exposure to any interferon, ribavirin, or other approved or experimental HCV-specific direct-acting antiviral agents at the time of initiation. Treatment-experienced patients include those who failed prior therapy with an interferon-based regimen (including null or partial response) or were intolerant to or ineligible for interferon-based therapy. Therapy discontinuation is recommended in patients with confirmed virologic breakthrough (&gt;1 log<sub>10</sub> units/mL increase in HCV RNA from nadir).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genotype 1b (treatment-naive or treatment-experienced, with or without compensated cirrhosis): 100 mg twice daily for 24 weeks in combination with daclatasvir</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genotype 1 or 4 (treatment-naive or treatment-experienced, with or without compensated cirrhosis): 100 mg twice daily for 24 weeks in combination with daclatasvir, peginterferon alfa, and ribavirin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> If within 8 hours of regularly scheduled time, missed dose should be taken as soon as remembered. If greater than 8 hours, missed dose should be skipped and the next dose should be administered at next regularly scheduled time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537361\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537362\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute (not receiving dialysis): 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: 100 mg twice daily; asunaprevir is removed by hemodialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537363\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate or severe impairment (Child-Pugh class B or C): Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537364\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Dose modifications or therapy interruption due to adverse reactions is not recommended when asunaprevir and daclatasvir are used in combination. If interruption of therapy is necessary, both agents must be stopped (ie, do not administer monotherapy); if therapy is resumed both agents must be started at the same time. Refer to peginterferon alfa and ribavirin monographs for dosing recommendations when used concurrently. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537366\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sunvepra: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46791860\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49955401\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537338\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C: </b>Treatment of chronic hepatitis C (CHC) in adult patients with hepatitis C virus (HCV) genotypes 1 or 4 and compensated liver disease, including cirrhosis. Must be administered as part of combination therapy with other anti-HCV agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537335\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46564756\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reactions reported in combination with daclatasvir, peginterferon alfa, and/or ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (12% to 39%), headache (6% to 28%), insomnia (4% to 21%), irritability (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (6% to 25%), skin rash (5% to 18%), alopecia (3% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (4% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (19%), neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (2% to 13%), increased serum ALT (4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation, hypertension, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Amnesia, anxiety, depression, disturbance in attention, dizziness, emotional lability, malaise, pain, sleep disorder, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis, eczema, erythema, exfoliative dermatitis, maculopapular rash, psoriasis, seborrheic dermatitis, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, dyspepsia, dysphagia, hemorrhoids, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Eosinophilia, leukopenia, lymphocytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (1% to 10%), hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, musculoskeletal chest pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, dyspnea, dyspnea on exertion, nasopharyngitis, oropharyngeal pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Erythema multiforme, reactivation of HBV (Health Canada, Dec. 15, 2016; Takayama 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537341\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to asunaprevir or any component of the formulation; moderate or severe hepatic impairment (Child-Pugh class B or C, score 7 or greater) or decompensated hepatic disease; concurrent use with daclatasvir, peginterferon alfa, and ribavirin in women who are pregnant or may become pregnant and men whose female partners are pregnant, may be pregnant, or plan to become pregnant; concurrent use with drugs dependent on the cytochrome P450 2D6 (CYP2D6) for clearance and for which elevated plasma concentrations are associated with serious ventricular arrhythmias and sudden death; concurrent use with moderate or strong inducers and inhibitors of CYP3A or with strong inhibitors of organic anion transporting polypeptide (OATP) 1B1 or 2B1. The following drugs are included in the manufacturer labeling as being contraindicated: Atazanavir, bosentan, carbamazepine, clarithromycin, cobicistat or cobicistat-containing regimens, cyclosporine, darunavir/ritonavir, dexamethasone, diltiazem, efavirenz, erythromycin, etravirine, flecainide, fluconazole, fosamprenavir, gemfibrozil, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, modafinil, nafcillin, nelfinavir, nevirapine, oxcarbazepine, phenobarbital, phenytoin, posaconazole, propafenone, rifabutin, rifampin, rifapentine, ritonavir, saquinavir, St. John's wort, telithromycin, thioridazine, verapamil, voriconazole</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537342\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity <b>[Canadian Boxed Warning]: Potential for hepatotoxicity. </b>In clinical trials, elevated ALT/AST accompanied by increases in total bilirubin with or without pyrexia or eosinophilia have been observed with regimens containing asunaprevir. Median time to onset in some clinical trials was 13 weeks (range: 4 to 24 weeks) and in most cases abnormalities resolved when therapy was either continued or discontinued. Monitor hepatic enzymes at least once every 2 weeks for the initial 12 weeks of therapy and every 4 weeks thereafter until therapy is completed. More frequent monitoring is required with upward trending ALT/AST levels. Discontinue therapy immediately if ALT &ge;10 x ULN and do not resume.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in mild hepatic impairment; monitor closely. Use in moderate or severe hepatic impairment (Child-Pugh class B or C) or with decompensated cirrhosis is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B virus reactivation <b>[Canadian Boxed Warning]: Potential for hepatitis B virus (HBV) reactivation.</b> Cases of HBV reactivation, sometimes resulting in fulminant hepatitis, hepatic failure, and death, have been reported in HCV/HBV co-infected patients during HCV treatment and/or post treatment with regimens containing direct-acting antivirals. Screen all patients for evidence of current or prior HBV infection prior to treatment initiation. Monitor patients with positive HBV serology (HBsAg positive) and patients with serologic evidence of resolved HBV infection (ie, HBsAg negative and anti-HBc positive) for HBV reactivation and treat as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment (CrCl &lt;30 mL/minute) who are not receiving hemodialysis; dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human immunodeficiency virus (HIV) coinfection: Safety and efficacy not established in patients coinfected with HIV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver-transplant patients: Safety and efficacy not established in liver transplant recipients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Must not be administered as monotherapy. Has not been studied in patients who have previously failed treatment regimens containing other HCV protease inhibitors. Safety and efficacy not established in patients with HCV genotypes 2, 3, 5, or 6.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: Therapy should be prescribed and monitored by a physician experienced in the treatment of CHC.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46361017\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), OATP1B1/SLCO1B1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate); <b>Induces</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46361014\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=108313&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): Asunaprevir may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Asunaprevir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Asunaprevir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Asunaprevir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Asunaprevir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Asunaprevir may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethinyl Estradiol: Asunaprevir may decrease the serum concentration of Ethinyl Estradiol.  Management: For patients using hormone-based contraception, a high-dose oral contraceptive containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone is recommended during treatment with asunaprevir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Asunaprevir may increase the serum concentration of Flecainide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Asunaprevir may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norelgestromin: Asunaprevir may decrease the serum concentration of Norelgestromin.  Management: For patients using hormone-based contraception, a high-dose oral contraceptive containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone is recommended during treatment with asunaprevir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norgestimate: Asunaprevir may decrease serum concentrations of the active metabolite(s) of Norgestimate.  Management: For patients using hormone-based contraception, a high-dose oral contraceptive containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone is recommended during treatment with asunaprevir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OATP1B1/SLCO1B1 Inhibitors: May increase the serum concentration of Asunaprevir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: Asunaprevir may increase the serum concentration of Propafenone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Asunaprevir. This effect is most likely with longer-term coadministration; single-dose rifampin may increase asunaprevir concentrations. RifAMPin may increase the serum concentration of Asunaprevir. This effect is likely following only single-dose or short-term rifampin administration.  Longer-term coadministration is likely to result in decreased asunaprevir concentrations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Asunaprevir may increase the serum concentration of Tacrolimus (Systemic). Specifically, this increase in tacrolimus concentrations may occur during the first week of combined therapy. Asunaprevir may decrease the serum concentration of Tacrolimus (Systemic). Specifically, this decrease in tacrolimus concentrations may occur with continued prolonged combination therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: Asunaprevir may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537339\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">According to the manufacturer, asunaprevir in combination with daclatasvir, peginterferon alfa, or ribavirin should not be administered during pregnancy, in women who are of childbearing potential not using contraception or partners of male patients receiving therapy. Women of childbearing potential and their male partners must use 2 forms of effective contraception during therapy and for at least 6 months after discontinuing therapy; routine pregnancy tests should be performed during this time period. For women using oral contraception, high-dose contraception containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone is recommended. Refer also to Ribavirin, Peginterferon Alfa, and Daclatasvir monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537340\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if asunaprevir is present in breast milk. Breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537365\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic enzymes (baseline then once every 2 weeks for initial 12 weeks then every 4 weeks thereafter during therapy; more frequent monitoring may be necessary as clinically indicated); serum HCV-RNA at baseline, during treatment, at the end of treatment, during treatment follow-up, and when clinically indicated; pretreatment and monthly pregnancy tests up to 6 months following discontinuation of therapy for women of childbearing age. Hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) prior to initiation; in patients with evidence of current or prior HBV infection, periodically monitor for clinical and laboratory signs of HBV reactivation during treatment and during posttreatment follow-up.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537345\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Asunaprevir is a direct acting antiviral agent (DAA) that inhibits the HCV NS3/4A serine protease complex which is responsible for processing the HCV polyprotein to yield mature viral proteins necessary for viral replication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537349\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 194 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 9.3%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic primarily by CYP3A; also a substrate of P-gp and OATP</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 17 to 23 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (84%; primarily as metabolites) and urine (&lt;1%; primarily as metabolites) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46682081\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Sunvepra (AU, CZ, HK, IL, JP, KR, SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Healthy Canadians Recalls &amp; Alerts. Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B. Health Canada website. Available at http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/61274a-eng.php?_ga=1.22701371.1869342618.1461941881. Published December 1, 2016. Accessed December 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26297529\"></a>Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. <i>Hepatol Res</i>. 2016;46(5):489-491.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/asunaprevir-united-states-not-available-drug-information/abstract-text/26297529/pubmed\" target=\"_blank\" id=\"26297529\">26297529</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 108313 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46537432\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46537336\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46537360\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46537361\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46537362\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46537363\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F46537364\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46537366\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46791860\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49955401\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46537338\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F46537335\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46564756\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46537341\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46537342\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46361017\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46361014\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46537339\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46537340\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46537365\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46537345\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46537349\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46682081\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/108313|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=asunaprevir-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Asunaprevir (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}